2021 CMSC Annual Meeting

Tag: (10)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More